Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at 2 Westchester Park Lane, Suite 208, White Plains, NY.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Tau inhibitor of tau self-association
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):